Urticaria Voices: Real-World Experience of Patients Living with Chronic Spontaneous Urticaria

被引：0
|
作者：
Karsten Weller [1 ]
Tonya Winders [2 ]
Jessica McCarthy [3 ]
Tara Raftery [4 ]
Pallavi Saraswat [5 ]
Cristina Constantinescu [6 ]
Maria-Magdalena Balp [7 ]
Jonathan A. Bernstein [8 ]
机构：
[1] Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin,Institute of Allergology, Charité – Universitätsmedizin Berlin
[2] Allergy and Asthma Network,Division of Rheumatology, Allergy and Immunology
[3] Global Allergy and Airways Patient Platform,undefined
[4] Novartis Pharmaceuticals Corporation,undefined
[5] Novartis Ireland Ltd.,undefined
[6] Novartis Healthcare Pvt. Ltd,undefined
[7] Ipsos SA,undefined
[8] Novartis Pharma AG,undefined
[9] University of Cincinnati,undefined
[10] Bernstein Allergy Group and Clinical Research Centre,undefined
来源：
Dermatology and Therapy | 2025年 / 15卷 / 3期
关键词：
Antihistamines; Angioedema; Chronic spontaneous urticaria; Disease/CU/symptom control; Physical symptoms; Psychological impact; Quality of life; Real world experience; Urticaria voices;
D O I：
10.1007/s13555-025-01348-8
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：747 / 761
页数：14
相关论文
共 50 条
  • [31] Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of "real-world' evidence
    Bernstein, Jonathan A.
    Kavati, Abhishek
    Tharp, Michael D.
    Ortiz, Benjamin
    MacDonald, Karen
    Denhaerynck, Kris
    Abraham, Ivo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (04) : 425 - 448
  • [32] OMALIZUMAB TREATMENT IS EFFECTIVE FOR PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA DESPITE DELAY IN TREATMENT INITIATION: A REAL-WORLD STUDY
    Rajput, Y.
    Thomas, C.
    Hetherington, J.
    Hoskin, B.
    Wrest, E.
    Holden, M.
    Bernstein, J. A.
    VALUE IN HEALTH, 2022, 25 (07) : S587 - S587
  • [33] Real-World Disease Burden of Chronic Urticaria and Vaccine Hesitancy
    Ban, Ga-Young
    Ye, Young -Min
    ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2023, 15 (01) : 1 - 3
  • [34] Factors associated with chronic spontaneous urticaria diagnostic and treatment delay in real-world clinical practice
    Seetasith, Arpamas
    Hetherington, James
    Keal, Aaron
    Salmon, Phoebe
    Holden, Michael
    Mosnaim, Giselle
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB80 - AB80
  • [35] Omalizumab in Chronic Spontaneous Urticaria: A Real-World Study on Effectiveness, Safety and Predictors of Treatment Outcome
    Chen, Jiaoquan
    Ou, Shanshan
    Wu, Weihong
    Zou, Hui
    Li, Huaping
    Zhu, Huilan
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2024, 17 : 1799 - 1808
  • [36] The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU
    Maurer, M.
    Abuzakouk, M.
    Berard, F.
    Canonica, W.
    Elberink, H. Oude
    Gimenez-Arnau, A.
    Grattan, C.
    Hollis, K.
    Knulst, A.
    Lacour, J-P
    Lynde, C.
    Marsland, A.
    McBride, D.
    Nakonechna, A.
    Ortiz de Frutos, J.
    Proctor, C.
    Sussman, G.
    Sweeney, C.
    Tian, H.
    Weller, K.
    Wolin, D.
    Balp, M-M.
    ALLERGY, 2017, 72 (12) : 2005 - 2016
  • [37] Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China
    Wang, Ao
    Yun, Yuhui
    Wen, Zhihua
    Gao, Yingxia
    Qi, Shuzhen
    Zhang, Yu
    Liang, Yunsheng
    Yao, Xu
    WORLD ALLERGY ORGANIZATION JOURNAL, 2022, 15 (12):
  • [38] Patient and physician perspectives on disease burden in chronic spontaneous urticaria A real-world US survey
    Mosnaim, Giselle
    Patil, Dhaval
    Kuruvilla, Merin
    Hetherington, James
    Keal, Aaron
    Mehlis, Stephanie
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2025, 134 (03)
  • [39] Patient demographics and real-world use of omalizumab for the treatment of chronic spontaneous/idiopathic urticaria in Canada
    Sussman, Gordon L.
    Lacuesta, Gina A.
    Hebert, Jacques
    Kanani, Amin S.
    Rihakova, Lenka
    Chiva-Razavi, Sima
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (02) : AB246 - AB246
  • [40] Omalizumab for severe chronic spontaneous urticaria (CSU)-real life experience of 251 patients
    Vadasz, Z.
    Asher, I
    Tal, Y.
    Rotem, M.
    Shichter-Confino, V
    Greif, Y.
    Kessel, A.
    Agmon-Levin, N.
    Benor, S.
    Lachover-Roth, I
    Zeldin, Y.
    Stein, M.
    Toker, O.
    Mahlab-Guri, K.
    Bezalel-Rosenberg, S.
    Hassoun, J.
    Toubi, E.
    Sthoeger, Z.
    ALLERGY, 2017, 72 : 716 - 716
12345